<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20920" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Efavirenz</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Yee</surname>
            <given-names>Jessica</given-names>
          </name>
          <aff>University of Saint Joseph School of Pharmacy</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Preuss</surname>
            <given-names>Charles V.</given-names>
          </name>
          <aff>University of South Florida</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jessica Yee declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Charles Preuss declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20920.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Efavirenz is an FDA-approved antiretroviral medication introduced in 1998 (and approved for use in the UE in 1999) that has played a pivotal role in the treatment and prevention of HIV. As a member of the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, efavirenz is an integral component of antiretroviral therapy (ART) regimens. By selectively inhibiting the reverse transcriptase enzyme, an essential catalyst for transcribing viral RNA into DNA, efavirenz disrupts the replication process of the human immunodeficiency virus. This module&#x000a0;discusses the indications, contraindications, mechanism of action, pharmacokinetics, dosing guidelines, adverse effects, and potential drug interactions associated with efavirenz while highlighting its role in combating HIV and providing clinicians with essential insights for optimal patient management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify potential candidates for efavirenz-based HIV therapy based on clinical guidelines and patient profiles.</p></list-item><list-item><p>Implement efavirenz therapy with appropriate dosing, emphasizing the importance of adherence and addressing concerns about adverse effects.</p></list-item><list-item><p>Assess patients regularly for medication efficacy and any adverse reactions, focusing on viral load suppression and CD4 count improvement.</p></list-item><list-item><p>Develop effective communication&#x000a0;with patients about efavirenz therapy, addressing potential adverse effects, adherence, and expectations.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20920&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20920">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20920.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Efavirenz is an FDA-approved medication used for the treatment and prevention of HIV-1 infection.&#x000a0;The drug is a non-nucleoside reverse transcriptase inhibitor (NNRTI). Like most other NNRTI agents, it&#x000a0;is commonly combined with other agents with different mechanisms of action in antiretroviral therapy (ART) regimens. However, efavirenz has recently fallen out of favor due to its unfavorable adverse effect profile.<xref ref-type="bibr" rid="article-20920.r1">[1]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>HIV infection in adults</p>
          </list-item>
          <list-item>
            <p>HIV infection in children aged 3 and older</p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Efavirenz is sometimes used off-label for HIV infection prevention (occupational exposure, perinatal transmission).</p>
      </sec>
      <sec id="article-20920.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Efavirenz is a non-nucleoside reverse transcriptase inhibitor drug (NNRTI); it binds to a non-catalytic site of the HIV reverse transcription enzyme, inhibiting its activity and resulting in DNA chain termination. This action blocks DNA polymerase activities, including HIV replication. Though therapeutic drug concentration monitoring is not necessary for efavirenz, it is&#x000a0;important to achieve adequate serum concentrations. Low concentrations are associated with virologic failure, while higher concentrations are associated with increased adverse effects such as sleep disorders.<xref ref-type="bibr" rid="article-20920.r2">[2]</xref>&#x000a0;Efavirenz is available in combination with other antiviral medications.<xref ref-type="bibr" rid="article-20920.r3">[3]</xref></p>
        <p>The administration of efavirenz with food has been shown to increase serum concentrations and the incidence of adverse effects. For this reason, patients should not take efavirenz with food.<xref ref-type="bibr" rid="article-20920.r4">[4]</xref>&#x000a0;Peak concentrations are reached within 5 hours following a single oral dose, with steady-state plasma concentrations achieved in 6 to 7 days. The half-life of efavirenz is roughly 45 hours, making once-daily dosing suitable. Efavirenz is highly protein-bound to human plasma proteins, predominantly albumin. Efavirenz converts to inactive hydroxylated metabolites by the action of the CYP3A4 enzyme.<xref ref-type="bibr" rid="article-20920.r5">[5]</xref>&#x000a0;</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Efavirenz is absorbed well following oral administration, and peak concentrations are achieved&#x000a0;5 hours after dosing. Steady-state plasma concentrations are&#x000a0;attained in 6&#x000a0;to 10 days.</p>
        <p><bold>Distribution:</bold> The volume of distribution for efavirenz is approximately 252 L.</p>
        <p><bold>Metabolism:</bold> Efavirenz metabolism primarily occurs&#x000a0;via the hepatic CYP450 enzyme system, specifically CYP2AB, into hydroxylated metabolites with subsequent glucuronidation. The drug is a primary CYP3A4 substrate.</p>
        <p><bold>Elimination:</bold> Excretion of efavirenz is via the feces (16% to 61%)&#x000a0;and urine (14% to 34%), with &#x0003c;1% unchanged. The drug's half-life is between 40 and 55 hours.<xref ref-type="bibr" rid="article-20920.r2">[2]</xref></p>
      </sec>
      <sec id="article-20920.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Efavirenz is available&#x000a0;as an oral capsule or tablet by prescription only.&#x000a0;Efavirenz is also available as a component of&#x000a0;2 combination formulations: efavirenz, emtricitabine, and tenofovir disoproxil fumarate; and efavirenz, lamivudine, and tenofovir disoproxil fumarate. The capsules are available&#x000a0;in 50 mg and 200 mg strengths, while the tablets are 600 mg.&#x000a0;The recommended adult dose is 600 mg/d, but some data show that 400 mg/d yields equivalent outcomes with fewer adverse effects.<xref ref-type="bibr" rid="article-20920.r6">[6]</xref>&#x000a0;Patients should not cut, crush, or chew the tablets.</p>
        <p>The administration of efavirenz with food has been shown to increase serum concentrations and the incidence of adverse effects.<xref ref-type="bibr" rid="article-20920.r4">[4]</xref>&#x000a0;Efavirenz dosing should be on an empty stomach, as increased efavirenz serum concentrations occur when taken with food. Increased serum concentrations can lead to increased adverse effects.<xref ref-type="bibr" rid="article-20920.r7">[7]</xref>&#x000a0;Efavirenz is often given in combination therapy with tenofovir and either emtricitabine or lamivudine.</p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>
<bold>HIV Infection</bold>
</p>
        <p>The dose is 600 mg orally, administered at bedtime.</p>
        <p>
<bold>HIV Prophylaxis (Off-Label)</bold>
</p>
        <p>Off-label HIV prophylaxis should be initiated as soon as possible after exposure but only following expert consultation. The optimal prophylaxis duration has not been established via empirical data and may differ according to institutional protocols.</p>
        <p>
<bold>Pediatric Dosing</bold>
</p>
        <p>The following dosing recommendations for efavirenz therapy for patients aged 3 and older are outlined below. These dosages are taken orally at bedtime.</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients 10 to 14.9 kg: 200 mg</p>
          </list-item>
          <list-item>
            <p>Patients 15 to 19.9 kg:&#x000a0;250 mg</p>
          </list-item>
          <list-item>
            <p>Patients 20 to 24.9 kg:&#x000a0;300 mg</p>
          </list-item>
          <list-item>
            <p>Patients 25 to 32.4 kg:&#x000a0;350 mg</p>
          </list-item>
          <list-item>
            <p>Patients 32.5 to&#x000a0;39.49 kg:&#x000a0;400 mg</p>
          </list-item>
          <list-item>
            <p>Patients &#x0003e;40 kg: 600 mg</p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;No dose adjustments are necessary for mild hepatic impairment (Child-Pugh class A), but caution is advisable. Efavirenz is not recommended in patients with moderate to severe impairment (Child-Pugh class B or C).&#x000a0;</p>
        <p><bold>Renal impairment:</bold>&#x000a0;The manufacturer recommends no renal dose adjustments. No data is available for patients on dialysis.</p>
        <p><bold>Pregnancy considerations:</bold> Efavirenz may be used during pregnancy if necessary, but there is a potential risk for fetal harm in the first trimester based on limited human data (pregnancy category D). Clinicians should obtain a negative pregnancy test before initiating treatment, and patients should avoid pregnancy with forms of contraception, with 1 of those being a barrier method, during treatment and for 12 weeks following treatment cessation in female patients. Patients should be enrolled in the Antiretroviral Pregnancy Registry.<xref ref-type="bibr" rid="article-20920.r8">[8]</xref></p>
        <p><bold>Breastfeeding considerations:</bold> Females using efavirenz should avoid breastfeeding, as there is a risk of postnatal HIV transmission despite ongoing HIV treatment. Research has not shown whether efavirenz affects maternal milk production.</p>
        <p><bold>Pediatric patients:</bold> See pediatric dosing above. Not approved for use in children younger than age 3.</p>
        <p><bold>Older patients:</bold>&#x000a0;Limited data regarding antiretroviral drugs and older patients is available. As HIV patients live longer, more studies are needed to determine the effects of age on antiretroviral therapy.<xref ref-type="bibr" rid="article-20920.r9">[9]</xref></p>
      </sec>
      <sec id="article-20920.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>As a drug class, NNRTIs are commonly associated with central nervous system (CNS) effects. These effects include impaired concentration, vivid or abnormal dreams, insomnia, suicidal ideation, nausea, and vomiting.<xref ref-type="bibr" rid="article-20920.r10">[10]</xref> Patients who experience these adverse effects are more likely to be non-adherent and discontinue their antiretroviral therapy, leading to anti-virologic therapeutic failure.<xref ref-type="bibr" rid="article-20920.r11">[11]</xref>&#x000a0;These symptoms typically arise in the first few days of treatment and decline within a few weeks of continued therapy.<xref ref-type="bibr" rid="article-20920.r5">[5]</xref>&#x000a0;Lipodystrophy is also a common adverse effect of all NNRTIs and may occur during treatment with efavirenz.<xref ref-type="bibr" rid="article-20920.r5">[5]</xref>&#x000a0;Other commonly encountered adverse events include rash, elevated AST or ALT, decreased neutrophils, hyperglycemia, and hyperlipidemia.</p>
        <p>Resistance&#x000a0;to NNRTIs, including efavirenz, occurs through reverse transcriptase gene mutations in the viral genome. Drug resistance can develop quickly when nonnucleoside reverse transcriptase inhibitors are used as monotherapy for HIV-1 infection. NNRTI-na&#x000ef;ve patients with previous nucleoside analog reverse transcriptase inhibitor (NRTI) exposure&#x000a0;with isolates&#x000a0;with resistance mutations and phenotypic resistance to NRTIs appear more likely to have hypersusceptibility to the NNRTI class of drugs.<xref ref-type="bibr" rid="article-20920.r12">[12]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Like most NNRTIs, efavirenz correlates with many drug interactions due to the phase I cytochrome P450 (CYP) enzymes. Efavirenz is an in vitro inhibitor of CYP3A4, CYP2C9, and CYP2C19. The drug is a substrate, inducer, and inhibitor of CYP3A4.<xref ref-type="bibr" rid="article-20920.r13">[13]</xref>&#x000a0;Medications&#x000a0;that&#x000a0;undergo metabolism through CYP2B6, 3A4, 2C9, and 2C19, and those that&#x000a0;undergo glucuronidation, may also interact with efavirenz.&#x000a0;Drugs that are contraindicated with efavirenz due to interactions include dasabuvir, grazoprevir, ritonavir, and voriconazole.<xref ref-type="bibr" rid="article-20920.r14">[14]</xref></p>
      </sec>
      <sec id="article-20920.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The use of efavirenz is contraindicated in patients with previously documented hypersensitivity to efavirenz and patients concurrently receiving elbasvir/grazoprevir due to a CYP3A4 interaction. Efavirenz should not be used in patients with Child-Pugh impairment class B or C. Efavirenz acts as a CYP3A4 inducer, in this case, by decreasing the serum concentrations of grazoprevir.<xref ref-type="bibr" rid="article-20920.r15">[15]</xref>&#x000a0;Efavirenz is also contraindicated in pregnant women in the first trimester due to reports of neural tube defects, and females should avoid breastfeeding. Caution is advised in patients who are poor CYP2B6 metabolizers.<xref ref-type="bibr" rid="article-20920.r16">[16]</xref></p>
      </sec>
      <sec id="article-20920.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Adolescent and adult patients should have LFTs measured at baseline, then 2 to 8 weeks following therapy initiation or with any change, then every 3 to 6 months. Lipid profiles are also recommended at baseline and every 6 to 12 months after that. Female patients of childbearing&#x000a0;age should have a baseline pregnancy test. Pediatric patients should have baseline LFTs with a 3 to 4-month follow-up and a baseline lipid profile with a 6 to 12-month follow-up.<xref ref-type="bibr" rid="article-20920.r17">[17]</xref>&#x000a0;As&#x000a0;a predominant adverse effect of efavirenz, psychiatric effects require monitoring in all patients. If these symptoms occur, the prescriber can attempt dose adjustments before changing medications.&#x000a0;</p>
      </sec>
      <sec id="article-20920.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The toxicity of this drug is generally relative to serum concentrations. Overdose is uncommon, and life-threatening sequelae from acute overdose are rare. There is no antidote&#x000a0;available for efavirenz overdose.&#x000a0;Short-term toxicity is usually transient and does not require treatment interruption.<xref ref-type="bibr" rid="article-20920.r18">[18]</xref></p>
      </sec>
      <sec id="article-20920.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Treatment with efavirenz can significantly improve the quality of life of patients infected with HIV, but its efficacy heavily relies on patient adherence. The neurologic adverse effects associated with efavirenz cause some patients to discontinue therapy. An interprofessional team of healthcare providers must become actively involved in caring for their HIV-positive patients. Key members of the team include pharmacists, physicians, advanced practice practitioners, nurses, and social workers. Obstacles to successful ART include a lack of social support and the financial burden of therapy. Healthcare providers must provide counsel regarding methods of coping with these adverse effects and promote medication adherence. Identifying appropriate opportunities for members of each discipline to provide care and encouragement is crucial to successful ART.<xref ref-type="bibr" rid="article-20920.r19">[19]</xref></p>
        <p>There are several recommendations for healthcare providers to assist in increasing successful outcomes in patients diagnosed with HIV on ART.<xref ref-type="bibr" rid="article-20920.r20">[20]</xref>&#x000a0;These recommendations include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Monitoring of successful entry into HIV care is recommended for individuals diagnosed with HIV. Nursing staff can play a significant role in this function and report their findings to the clinical team.&#x000a0;Entry into care, defined as a visit with an HIV care provider, has demonstrated correlations with improved survival.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Providers should obtain self-reported adherence routinely. Healthcare providers should ask patients about their appointment adherence. Nursing staff can play a significant role here in assessing pharmacotherapy adherence.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pharmacy refill data is recommended for adherence monitoring if medication refills are not automatically sent to patients.&#x000a0;Pharmacy refill data can help to confirm self-reported adherence. If the pharmacist notices irregular refill activity, they should respond immediately, contacting both the patient and the prescriber.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>If regimens have equivalent efficacy, switching treatment-experienced patients receiving complex or poorly tolerated regimens to simpler once-daily regimens is recommended.&#x000a0;A higher tablet/capsule burden is associated with lower adherence. Discussing the patient's tablet/capsule burden can identify an opportunity to improve compliance. The pharmacist can advise on newer combination formulations that decrease tablet/capsule burden.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Individual one-on-one ART education is recommended.&#x000a0;Counseling, skills-building, and education increase adherence rates, which are crucial to therapeutic success.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Interprofessional education and counseling intervention approaches are recommended. Interprofessional teams can provide education regarding multiple factors that affect adherence.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Case management is necessary to minimize the number of adherence barriers in people experiencing homelessness.&#x000a0;Assistance in acquiring mental health and substance abuse treatment and housing accommodations can significantly improve outcomes.</p>
          </list-item>
        </list>
        <p>In summary, efavirenz therapy requires an interprofessional team approach, including&#x000a0;all interprofessional healthcare team members collaborating across disciplines and engaging in open communication to achieve optimal patient outcomes.</p>
      </sec>
      <sec id="article-20920.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20920&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20920">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20920/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20920">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20920.s11">
        <title>References</title>
        <ref id="article-20920.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caniglia</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sabin</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Winston</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Logan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gill</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vandenhende</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Barger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lodi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moreno</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Arribas</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Pacheco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cardoso</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Chrysos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gogos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Abgrall</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Costagliola</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Seng</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>van Sighem</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reiss</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Muga</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hoyos</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hauser</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barrufet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Leyes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tate</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Justice</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;n</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2018</year>
            <month>Jan</month>
            <day>01</day>
            <volume>77</volume>
            <issue>1</issue>
            <fpage>102</fpage>
            <page-range>102-109</page-range>
            <pub-id pub-id-type="pmid">28991888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20920.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McDonagh</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Alvarellos</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Altman</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>PharmGKB summary: Efavirenz pathway, pharmacokinetics.</article-title>
            <source>Pharmacogenet Genomics</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>25</volume>
            <issue>7</issue>
            <fpage>363</fpage>
            <page-range>363-76</page-range>
            <pub-id pub-id-type="pmid">25966836</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20920.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Desta</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Gammal</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Whirl-Carrillo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gaur</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Sukasem</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hockings</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Swart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tyndale</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Masimirembwa</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Iwuchukwu</surname>
                <given-names>OF</given-names>
              </name>
              <name>
                <surname>Chirwa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lennox</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gaedigk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>106</volume>
            <issue>4</issue>
            <fpage>726</fpage>
            <page-range>726-733</page-range>
            <pub-id pub-id-type="pmid">31006110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20920.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robarge</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Metzger</surname>
                <given-names>IF</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thong</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Skaar</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Desta</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Bies</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>61</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">27799204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20920.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maggiolo</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Efavirenz: a decade of clinical experience in the treatment of HIV.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>64</volume>
            <issue>5</issue>
            <fpage>910</fpage>
            <page-range>910-28</page-range>
            <pub-id pub-id-type="pmid">19767318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20920.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>ENCORE1 Study Group</collab>
              <name>
                <surname>Carey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Puls</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Losso</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Phanupak</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Foulkes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mohapi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Crabtree-Ramirez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jessen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Winston</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Belloso</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Emery</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.</article-title>
            <source>Lancet Infect Dis</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>15</volume>
            <issue>7</issue>
            <fpage>793</fpage>
            <page-range>793-802</page-range>
            <pub-id pub-id-type="pmid">25877963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20920.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Homkham</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cressey</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Bouazza</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ingsrisawang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Techakunakorn</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mekmullica</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Borkird</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Puangsombat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Na-Rajsima</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Treluyer</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Urien</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jourdain</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Role of efavirenz plasma concentrations on long-term HIV suppression and immune restoration in HIV-infected children.</article-title>
            <source>PLoS One</source>
            <year>2019</year>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>e0216868</fpage>
            <pub-id pub-id-type="pmid">31095608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20920.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Portwood</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sexton</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kumarendran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brandon</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kirtley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hemelaar</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Perinatal outcomes associated with combination antiretroviral therapy compared with monotherapy.</article-title>
            <source>AIDS</source>
            <year>2023</year>
            <month>Mar</month>
            <day>01</day>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>489</fpage>
            <page-range>489-501</page-range>
            <pub-id pub-id-type="pmid">36695359</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20920.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stader</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Courlet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kinvig</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Battegay</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Decosterd</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Penny</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Siccardi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marzolini</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>87</volume>
            <issue>2</issue>
            <fpage>458</fpage>
            <page-range>458-470</page-range>
            <pub-id pub-id-type="pmid">32470203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20920.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Apostolova</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Blas-Garcia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Galindo</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Esplugues</surname>
                <given-names>JV</given-names>
              </name>
            </person-group>
            <article-title>Efavirenz: What is known about the cellular mechanisms responsible for its adverse effects.</article-title>
            <source>Eur J Pharmacol</source>
            <year>2017</year>
            <month>Oct</month>
            <day>05</day>
            <volume>812</volume>
            <fpage>163</fpage>
            <page-range>163-173</page-range>
            <pub-id pub-id-type="pmid">28690189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20920.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Antiretroviral Regimens: Adverse Effects and Tolerability Failure that Cause Regimen Switching.</article-title>
            <source>Infect Chemother</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>47</volume>
            <issue>4</issue>
            <fpage>231</fpage>
            <page-range>231-8</page-range>
            <pub-id pub-id-type="pmid">26788406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20920.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hinay</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Kanai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tsuneki-Tokunaga</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Komatsu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Telan</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Kageyama</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>In Vitro Susceptibility of HIV Isolates with High Growth Capability to Antiretroviral Drugs.</article-title>
            <source>Int J Mol Sci</source>
            <year>2022</year>
            <month>Dec</month>
            <day>06</day>
            <volume>23</volume>
            <issue>23</issue>
            <pub-id pub-id-type="pmid">36499705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20920.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Desta</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19.</article-title>
            <source>Drug Metab Pharmacokinet</source>
            <year>2013</year>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>362</fpage>
            <page-range>362-71</page-range>
            <pub-id pub-id-type="pmid">23385314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20920.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gausi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wiesner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Norman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wallis</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Onyango-Makumbi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chipato</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Browning</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chakhtoura</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Montepiedra</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Aaron</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bradford</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vhembo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Stranix-Chibanda</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Masheto</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Violari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mmbaga</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Aurpibul</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bhosale</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nevrekhar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rouzier</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kabugho</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mutambanengwe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chanaiwa</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Nyati</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mhembere</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tongprasert</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hesseling</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zimmer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Costello</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jean-Philippe</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sterling</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Theron</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Weinberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Denti</surname>
                <given-names>P</given-names>
              </name>
              <collab>IMPAACT P1078 (TB APPRISE) Study Group Team</collab>
            </person-group>
            <article-title>Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>109</volume>
            <issue>4</issue>
            <fpage>1034</fpage>
            <page-range>1034-1044</page-range>
            <pub-id pub-id-type="pmid">32909316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20920.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rice</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Faragon</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Banks</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chirch</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals.</article-title>
            <source>J Clin Transl Hepatol</source>
            <year>2016</year>
            <month>Sep</month>
            <day>28</day>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>234</fpage>
            <page-range>234-240</page-range>
            <pub-id pub-id-type="pmid">27777891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20920.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ford</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Niehaus</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Joubert</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pepper</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Pharmacogenetics of <italic>CYP2A6</italic>, <italic>CYP2B6</italic>, and <italic>UGT2B7</italic> in the Context of HIV Treatments in African Populations.</article-title>
            <source>J Pers Med</source>
            <year>2022</year>
            <month>Dec</month>
            <day>05</day>
            <volume>12</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">36556234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20920.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khemla</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Meesing</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sribenjalux</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chetchotisakd</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir.</article-title>
            <source>Drug Target Insights</source>
            <year>2023</year>
            <season>Jan-Dec</season>
            <volume>17</volume>
            <fpage>45</fpage>
            <page-range>45-53</page-range>
            <pub-id pub-id-type="pmid">37153647</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20920.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nazziwa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sekadde</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kanyike</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wobudeya</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nabukeera-Barungi</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Efavirenz poisoning in a 12 year old HIV negative African boy.</article-title>
            <source>Pan Afr Med J</source>
            <year>2012</year>
            <volume>12</volume>
            <fpage>86</fpage>
            <pub-id pub-id-type="pmid">23077707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20920.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chendi</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Okomo Assoumou</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Yekwa</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Lyonga</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mesembe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eyoh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ikomey</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48&#x02009;weeks in Yaound&#x000e9;, Cameroon: a longitudinal cohort study.</article-title>
            <source>BMC Infect Dis</source>
            <year>2019</year>
            <month>Feb</month>
            <day>26</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>194</fpage>
            <pub-id pub-id-type="pmid">30808298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20920.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thompson</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Mugavero</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Amico</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Cargill</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Orrell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Altice</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Bangsberg</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Bartlett</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Beckwith</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Dowshen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Horn</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Stirratt</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Remien</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Simoni</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Nachega</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel.</article-title>
            <source>Ann Intern Med</source>
            <year>2012</year>
            <month>Jun</month>
            <day>05</day>
            <volume>156</volume>
            <issue>11</issue>
            <fpage>817</fpage>
            <page-range>817-33, W-284, W-285, W-286, W-287, W-288, W-289, W-290, W-291, W-292, W-293, W-294</page-range>
            <pub-id pub-id-type="pmid">22393036</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
